Lexicon Total Liab from 2010 to 2025
| LXRX Stock | USD 0.36 0.02 5.88% |
Total Liabilities | First Reported 2000-03-31 | Previous Quarter 142.6 M | Current Value 152.5 M | Quarterly Volatility 101.5 M |
Check Lexicon Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lexicon Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 507.3 K, Interest Expense of 16.4 M or Total Revenue of 45.7 M, as well as many indicators such as Price To Sales Ratio of 7.22, Dividend Yield of 0.0 or PTB Ratio of 1.54. Lexicon financial statements analysis is a perfect complement when working with Lexicon Pharmaceuticals Valuation or Volatility modules.
Lexicon | Total Liab |
Latest Lexicon Pharmaceuticals' Total Liab Growth Pattern
Below is the plot of the Total Liab of Lexicon Pharmaceuticals over the last few years. It is the total amount of all liabilities that a company has, including both short-term and long-term liabilities. Lexicon Pharmaceuticals' Total Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Lexicon Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Total Liab | 10 Years Trend |
|
Total Liab |
| Timeline |
Lexicon Total Liab Regression Statistics
| Arithmetic Mean | 175,792,607 | |
| Geometric Mean | 126,488,839 | |
| Coefficient Of Variation | 69.73 | |
| Mean Deviation | 101,925,045 | |
| Median | 149,689,713 | |
| Standard Deviation | 122,578,975 | |
| Sample Variance | 15025.6T | |
| Range | 370.3M | |
| R-Value | (0.03) | |
| Mean Square Error | 16086.1T | |
| R-Squared | 0.0008 | |
| Significance | 0.92 | |
| Slope | (725,242) | |
| Total Sum of Squares | 225384.1T |
Lexicon Total Liab History
About Lexicon Pharmaceuticals Financial Statements
Lexicon Pharmaceuticals investors use historical fundamental indicators, such as Lexicon Pharmaceuticals' Total Liab, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Lexicon Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Total Liabilities | 152.5 M | 149.7 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Additional Tools for Lexicon Stock Analysis
When running Lexicon Pharmaceuticals' price analysis, check to measure Lexicon Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lexicon Pharmaceuticals is operating at the current time. Most of Lexicon Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Lexicon Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lexicon Pharmaceuticals' price. Additionally, you may evaluate how the addition of Lexicon Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.